COVID-19 rapid guideline: dermatological conditions treated with drugs affecting the immune response
The purpose of this Guidelines summary is to maximise the safety of children and adults who have dermatological conditions treated with drugs affecting the immune response during the COVID-19 pandemic.
This Guidelines summary includes recommendations on recognition and diagnosis of actinic keratosis, use of clinical findings, management and options for treatment. It includes an algorithm of the pathway from recognition to treatment in primary care, including red flags to recognise.
This guideline sets out an antimicrobial prescribing strategy for adults with leg ulcer infection. It aims to optimise antibiotic use and reduce antibiotic resistance.
This summary has been developed for use by community pharmacists under our Guidelines for Pharmacy title and therefore only covers the information relevant to this setting. Areas covered include: treatment and management, advantages and disadvantages of treatment options, information and advice for those with the condition. Please refer to the full guideline for the complete set of recommendations.
This summary covers an antimicrobial strategy for patients with cellulitis and erysipelas
Implementing the Primary Care Dermatology Society guideline and primary care treatment pathway for actinic (solar) keratosis
Information intended for healthcare professionals only. Guidelines in Practice approached Almirall Ltd for an educational grant to support the production of an implementation checklist. Please see the bottom of the page for full disclaimer.